Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
Johnson and Johnson
McKinsey
Dow

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)

See Plans and Pricing

« Back to Dashboard

ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)

Docket   Start Trial Date Filed 2006-04-28
Court District Court, D. New Jersey Date Terminated 2009-09-30
Cause 35:271 Patent Infringement Assigned To Freda L. Wolfson
Jury Demand None Referred To Magistrate Judge Tonianne J. B
Parties GILBERTO FELIX; JONATHAN LEE RICHES; RANBAXY INC.; RANBAXY LABORATORIES LIMITED; ROCHE PALO ALTO LLC
Patents 4,355,032; 6,083,953
Attorneys BROOKS R. BRUNEAU; DAVID E. DELORENZI; DIANE C. RAGOSA; ERICA SUSAN HELMS; GILBERTO FELIX; JEFFREY Z.Y. LIAO; JONATHAN LEE RICHES; KAREN A. CONFOY; KRISTINE L. BUTLER; ROBERT G. SHEPHERD; SHEILA F. MCSHANE; THOMAS J. MELORO , JR.; VINNY LEE
Firms Gilberto Felix; Parker Ibrahim & Berg LLC; WILLIAMSBURG, FEDERAL CORRECTIONAL INSTITUTION, Inmate Mail/Parcels; Willkie Farr & Gallagher, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for ROCHE PALO ALTO LLC v. RANBAXY LABORATORIES LIMITED (D.N.J. 2006)

Date Filed Document No. Description Snippet Link To Document
2008-03-19 135 United States Patent, No. 6,083,953 (the “953 Patent”). Ranbaxy argues that the ‘953 Patent is invalid … the ‘953 Patent. (Liao Decl. Ex. 9 at R0043851). On October 14, 1999, before the patent issued, Roche…entitled to a patent unless he himself did not invent the subject matter sought to be patented. 35 U.S.C…of an actual inventor from a patent, the court must declare the patent invalid. Id. at 1349. A party…rendered the patent invalid. Section 256 affords the opportunity to correct the patent.”); see also S External link to document
2009-02-17 277 infringement of Roche’s U.S. Patent No. 6,083,953 (“the ‘953 patent”). This action was precipitated…evidence” of the patent, viz., the claim language itself, the patent specification and the patent's prosecution… of Roche’s ‘953 patent. B. CMV, Valcyte, And The ’953 Patent 2. Cytomegalovirus…product would not infringe the ’953 patent because the patent requires the claimed valganciclovir hydrochloride…Compounds Of The ‘953 Patent Claims 122. The compounds of the ‘953 patent claims are mono-ester External link to document
2009-09-30 302 Roche, as the assignee of U.S. Patent No. 4,355,032 that described and claimed ganciclovir…Roche’s United States Patent No. 6,083,953 (the “‘953 patent”). The ‘953 patent includes claims to the… Beauchamp”) prior patent, United States Patent No. 5,043,339 (the “‘339 patent”), and papers teach… Patent Cooperation Treaty PTO Patent and Trademark Office…collectively, “Ranbaxy”) for patent infringement in violation of the Patent and the Food and Drug Laws External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.